#USA #biotechnology #HealthCONx #Amgen #Thousand Oaks

Amgen to Present at the Evercore HealthCONx Conference

On December 4, 2024, Amgen (NASDAQ: AMGN) will take part in the 7th Annual Evercore HealthCONx Conference, which has become a hallmark event in the healthcare sector. At 10:00 a.m. ET, the company will host a session featuring prominent executives in a fireside chat format. Peter Griffith, the Executive Vice President and Chief Financial Officer, along with Jay Bradner, the Executive Vice President of Research and Development, and Chief Scientific Officer, will join Susan Sweeney, Executive Vice President for Obesity and Related Conditions.

This event will be broadcast live via webcast and will be accessible to a wide audience, including media members, investors, and the general public. Interested parties can find more detailed information regarding the presentation times and streaming availability on Amgen's Investor Relations Events Calendar.

How to Access the Webcast

For those who wish to attend virtually, the webcast will be made available on Amgen’s official website. It will later be archived for 90 days, allowing for on-demand access to those who are unable to join live.

What to Expect from the Conference

The Evercore HealthCONx Conference serves as a pivotal platform for companies to showcase their latest innovations and strategic directions in the healthcare landscape. Amgen, being a pioneer in biotechnology, continues to advance in its mission to develop advanced therapies that address critical medical conditions. The discussions at this conference are anticipated to shed light on Amgen's innovative approaches, their current portfolio, and future projects in the pipeline.

Amgen's Distinction in the Biotechnology Field

Established over 40 years ago, Amgen has been at the forefront of the biotechnology revolution, discovering and creating therapies that address some of the most challenging health issues globally. The company’s commitment to innovation remains steadfast, as evidenced by its cutting-edge research and substantial investment in developing medicines aimed at treating diseases such as cancer, cardiovascular conditions, osteoporosis, and rare disorders.

Amgen's sustained efforts have earned it numerous accolades, including recognition from Fast Company as one of the “World’s Most Innovative Companies” and “America’s Best Large Employers” by Forbes in 2024. Additionally, Amgen is recognized as a part of the Dow Jones Industrial Average® and the Nasdaq-100 Index®, marking its impact and influence within the capital market.

Recent Achievements and Future Endeavors

In recent years, Amgen has introduced groundbreaking therapies and expanded its therapeutic areas to meet the evolving needs of patients. This includes advancements in biotechnology that leverage human genetic data, reflecting a deep commitment to transforming patient care through scientific innovation.

As a part of its ongoing mission, Amgen focuses on maintaining high standards in their operations, evidenced by the sustained recognition of their workplace environment and efforts in climate leadership by reputable organizations.

Join the Conversation

Individuals interested in Amgen’s developments and innovations are encouraged to tune in on December 4, 2024, for insights from its leadership team, and stay informed about their contributions to health care. Follow Amgen on platforms like X (formerly Twitter), LinkedIn, Instagram, TikTok, YouTube, and Threads for the latest updates and announcements.

For more information about the event or Amgen’s initiatives, visit Amgen.com. There, you can also access a wealth of resources that detail their ongoing commitment to discovering, developing, manufacturing, and delivering life-altering treatments for patients across the globe.